**Name of journal: World Journal of Gastroenterology**

**ESPS Manuscript NO: 27685**

**Manuscript Type: SYSTEMATIC REVIEWS**

**Clinical guidelines of non-alcoholic fatty liver disease: A systematic review**

Zhu J *et al.* Non-alcoholic fatty liver disease guidelines

**Jin-zhou Zhu, Kelseanna Hollis-Hansen, Xing-yong Wan, Su-juan Fei, Xun-lei Pang, Fan-dong Meng, Chao-hui Yu, You-ming Li**

**Jin-zhou Zhu, Xing-yong Wan, Chao-hui Yu, You-ming Li**, Department of Gastroenterology, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou 310003, Zhejiang Province, China

**Kelseanna Hollis-Hansen**, Systems-oriented Global Childhood Obesity Intervention Program, Department of Epidemiology and Environmental Health, University at Buffalo, The State University of New York, Buffalo, NY 14214, United States

**Su-juan Fei, Xun-lei Pang,** Department of Gastroenterology, The Affiliated Hospital, Xuzhou Medical University, Xuzhou 221000, jiangsu Province, China

**Fan-dong Meng,** Department of Endocrinology, The Affiliated Hospital, Xuzhou Medical University, Xuzhou 221000, jiangsu Province, China

**Author contributions:** Zhu J and Hollis-Hansen K contributed equally to the work; Zhu J collected data; Hollis-Hansen K performed analyses and wrote manuscript; Wan XY, Fei SJ and Pang XL performed systematic evaluation; Meng FD revised the manuscript; Yu CH and Li YM contributed to the study design; all authors reviewed and approved the final manuscript as submitted.

**Supported by** the National Natural Science Foundation of China, No. 81170378 and No. 81230012.

**Conflict-of-interest statement:** All authors have no conflict of interest related to the manuscript.

**Data sharing:** No additional data are available.

**Open-Access:** This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>

**Manuscript source:** Unsolicited manuscript

**Correspondence to:** **Dr. You-ming Li, Professor,** Department of Gastroenterology, The First Affiliated Hospital, Zhejiang University, 79 Qingchun Road, Hangzhou 310003, Zhejiang Province, China. ymli.zju@live.com

**Telephone:** +86-15665170166

**Fax:** +86-571-87080565

**Received:** June 11, 2016

**Peer-review started:** June 15, 2016

**First decision:** August 8, 2016

**Revised:** August 11, 2016

**Accepted:** August 23, 2016

**Article in press:**

**Published online:**

**Abstract**

**AIM:** To perform a systematic review to grade guidelines and present recommendations for clinical management of non-alcoholic fatty liver disease (NAFLD).

**METHODS:** A database search was conducted on PubMed for guidelines published before May 2016, supplemented by reviewing relevant websites. The Appraisal of Guidelines for Research and Evaluation (ARGEE) instrument II was a tool designed to appraise the methodological rigor and transparency in which a clinical guideline is developed and it is used internationally. It was used to appraise the quality of guidelines in this study. The inclusion criteria include: clinical NAFLD guidelines for adults, published in English, and released by governmental agencies or key organizations.

**RESULTS:** Eleven guidelines were included in this study. Since 2007, guidelines have been released in Asia (3 in China, 1 in South Korea, and 1 in Japan), Europe (1 in Italy), America (1 in United States and 1 in Chile) and three international agencies [European associations joint, Asia–Pacific Working Party and World Gastroenterology Organization (WGO)]. Using the ARGEE II instrument, we found US 2012 and Europe 2016 had the highest scores, especially in the areas of rigor of development and applicability. Additionally, Italy 2010 and Korea 2013 also presented comprehensive content, rigorous procedures and good applicability. And WGO 2014 offered various algorithms for clinical practice. Lastly, a practical algorithm for the clinical management was developed, based on the recommended guidelines.

**CONCLUSION:** This is the first systematic review of NAFLD guidelines. It may yield insights for physicians and policy-makers in the development and application of guidelines.

**Key words:** Diagnosis; Management; Non-alcoholic fatty liver disease; Systematic review; Treatment

**© The Author(s) 2016.** Published by Baishideng Publishing Group Inc. All rights reserved.

**Core tip:** Non-alcoholic fatty liver disease (NAFLD) is one of the leading chronic liver diseases globally. A comprehensive study of NAFLD guidelines will be useful for various stakeholders to develop and utilize guidelines. This is the first systematic review to grade NAFLD guidelines and present recommendations for the clinical management of NAFLD. Through systematically evaluating the published guidelines and offering a clinical algorithm, it may yield insights for physicians and policy-makers in the development and application of guidelines.

Zhu Jz, Hollis-Hansen K, Wan Xy, Fei Sj, Pang Xl, Meng Fd, Yu Ch, Li Ym. Clinical guidelines of non-alcoholic fatty liver disease: A systematic review. *World J Gastroenterol* 2016; In press

**INTRODUCTION**

Non-alcoholic fatty liver disease (NAFLD) encompasses a spectrum of disease ranging from simple hepatic steatosis, to inflammatory non-alcoholic steatohepatitis (NASH) with increasing levels of fibrosis and eventually hepatic cirrhosis[[1](#_ENREF_1)]. According to the latest guideline released in Europe[[2](#_ENREF_2)], it is defined by the presence of steatosis in > 5% hepatocytes, in the absence of other causes attributed to hepatic steatosis[[3](#_ENREF_3)]. Recent advance supports NAFLD as the chronic liver disease component of metabolic syndrome[[4](#_ENREF_4)].

Younossi *et al*[[5](#_ENREF_5)] estimated the global prevalence of imaging-diagnostic NAFLD arrived at 25%, although it varied by region and age. In the United States, it was reported to be between 10% and 30%, which is similar to rates in Europe and Asia[[6-8](#_ENREF_6)]. It is alarming that the prevalence of NAFLD worldwide is on the rise[[9](#_ENREF_9)], along with the associated disorders: obesity, insulin resistance, diabetes and metabolic syndrome[[8](#_ENREF_8)]. New evidence supports NAFLD as a common liver disease presenting across the globe, which warrants the attention of physicians, researchers, and national policy makers. However, gaps between provider knowledge and awareness of clinical practice guidelines exist.

Offering continuing education and developing high-quality national guidelines may help making inroads into the problem of suboptimal NAFLD care. A comprehensive study of the existing guidelines of NAFLD might be useful for helping stakeholders, including physicians, patients, policymakers and governmental bodies to develop and implement guidelines. To our knowledge, this is the first systematic critical appraisal of published guidelines to systematically grade and comprehensively present the evidence-based recommendations for the diagnosis and treatment of NAFLD.

**Materials and methods**

This systematic review was conducted according to the PRISMA guidelines[[10](#_ENREF_10)].

***Electronic database search***

The database search was conducted on PubMed for guidelines published before May 2016. In the search, we used the following key words and terms: ("fatty liver"[Title]) AND (strategy\*[Title] OR guideline\*[Title] OR recommendation\*[Title] OR management\*[Title]).

***Websites searches***

The literature search was supplemented by searching relevant websites (using the term "fatty liver"), including the following: (1) Australia National Health and Medical Research Council ([www.nhmrc.gov.au](http://www.nhmrc.gov.au)); (2) American College of Physicians ([www.acponline.org)](http://www.acponline.org)); (3) American Medical Association ([http://www.ama-assn.org/ama)](http://www.ama-assn.org/ama%29); (4) Canadian Medical Association ([www.cma.ca)](http://www.cma.ca)); (5) Institute for Clinical Systems Improvement (<http://www.icsi.org)>; (6) Institute of Medicine ([www.iom.edu/)](http://www.iom.edu/%29); (7) National Guidelines Clearinghouse ([www.guideline.gov)](http://www.guideline.gov)); (8) National Institute for Health and Clinical Excellence ([www.nice.org.uk)](http://www.nice.org.uk)); (9) Royal College of Physicians (<https://www.rcplondon.ac.uk)>; (10) Scottish Intercollegiate Guidelines Network ([www.sign.ac.uk)](http://www.sign.ac.uk)); and (11) World Health Organization ([www.who.int)](http://www.who.int)).

***Inclusion criteria and guidelines selection***

The guideline was included in this study, if it met the following criteria: (1) clinical guidelines regarding the diagnosis and management of NAFLD in adults; (2) released by governmental agencies or key health organizations; and (3) published in English. Two investigators independently performed the screen on PubMed and the websites, according to the inclusion criteria. Discrepancies were resolved by the involvement of a third reviewer.

***The Appraisal of Guidelines for Research and Evaluation instrument II***

The Appraisal of Guidelines for Research and Evaluation (AGREE) II was a tool designed to appraise the methodological rigor and transparency in which a clinical guideline is developed and it is used internationally. It consists of 23 items grouped in 6 domains, i.e. scope and purpose, stakeholder involvement, rigor of development, clarity and presentation, applicability and editorial independence[[11](#_ENREF_11)].

**RESULTS**

***Guidelines included in the study***

As shown in Figure 1, eleven guidelines met the criteria and were included in the final version of this systematic review. Since 2007, five guidelines were released in Asia (3 in China, 1 in Japan and 1 in South Korea), while three guidelines were released in the United States, Italy and Chile, respectively (Table 1). Three guidelines were released by international agencies, *i.e.* Asia–Pacific Working Party, World Gastroenterology Organization (WGO) and a joint commission of European associations.

***Guidelines quality scores***

Eleven guidelines were appraised according to AGREE II, as presented in Table 1 and Figure 2. We highly recommended the two guidelines, United States 12[[1](#_ENREF_1)] and Europe 16[[2](#_ENREF_2)], given the high scores and the authority of the organizations. Additionally, Italy 10[[12](#_ENREF_12)] and South Korea 13[[13](#_ENREF_13)] also presented comprehensive content, rigorous procedures and good applicability. Lastly, WGO 14[[14](#_ENREF_14)] offered a variety of algorithms for clinical practice.

***Clinical algorithm***

Figure 3presented a clinical algorithm for the diagnosis and management of NAFLD in adults. Generally, the procedure of clinical practice includes diagnosis, assessment, and management.

**DISCUSSION**

This is the first systematic critical appraisal to grade the guidelines and present the evidence-based recommendations for the clinical management of NAFLD. Using the ARGEE II instrument, we found United States 12[[1](#_ENREF_1)] and Europe 16[[2](#_ENREF_2)] had the highest scores, especially in the areas of rigor of development and applicability. Additionally, we developed a clinical algorithm for the diagnosis and management of NAFLD in adults.

NAFLD is one of the leading chronic liver diseases in the world[[5](#_ENREF_5)]. While incidence rates may possibly vary and/or be underreported[[15](#_ENREF_15),[16](#_ENREF_16)], the present situation reinforces the need for a precise and rational system of management for NAFLD. Additionally, the obesity epidemic has led to a rapidly increasing population at risk for NAFLD, and shows no signs of slowing down. Therefore, NAFLD will only become a larger problem in the future if it is not properly prevented and managed now.

Currently, liver biopsy has still been regarded as the gold standard in the diagnostic evaluation of NAFLD[[17](#_ENREF_17)]. However, a biopsy is an invasive practice, which carries a series of medical risks, *e.g*. hemorrhage and infection[[2](#_ENREF_2)]. The non-invasive assessing method that is most suitable for evaluating hepatic steatosis is ultrasound, with a sensitivity of 60%-94% and a specificity of 66%-97%[[18](#_ENREF_18)], even though it presents less precise in milder degrees of steatosis. Given the widely availability and economic efficiency, ultrasound is recommended as a first-line diagnostic test in most guidelines, rather than liver biopsy and other imaging tools. Additionally, a variety of noninvasive algorithms, based on metabolic and anthropometric tests, have been developed for identifying NAFLD, e.g. the fatty liver index[[19](#_ENREF_19)] and the hepatic steatosis index[[20](#_ENREF_20)]. They have been utilized to screen subjects with hepatic steatosis in large epidemiologic studies or predicting potential patients in clinical practice[[18](#_ENREF_18)]. The development of more accurate and noninvasive diagnostic tools is still a major unmet demand in the clinic.

In terms of treatment, the pathophysiological association between NAFLD and obesity-related diseases, *e.g.* metabolic syndrome and diabetes, supports structured programs of lifestyle intervention aimed at weight loss, before or in addition to pharmacotherapy[[3](#_ENREF_3),[21](#_ENREF_21)]. The elements of a comprehensive lifestyle approach generally include energy restriction, macronutrient composition, alcohol consumption, coffee drinking and physical activity[[2](#_ENREF_2)]. Furthermore, published guidelines suggested pharmacotherapy should be exclusively indicated for early-stage NASH with increased risk of advanced NASH[[2](#_ENREF_2),[22](#_ENREF_22)]. The past decade has witnessed some advance in clinical pharmacotherapy trials, e.g. the use of metformin, pioglitazone and vitamin E, however most NASH patients failed to respond to these methods[[2](#_ENREF_2),[23](#_ENREF_23)]. When considering safety and tolerability, no drug has been approved for NAFLD by pharmacological agencies by now, while no specific drug therapy was firmly recommended in the present guidelines[[2](#_ENREF_2)]. Therefore, it is still imperative to continue research to improve pharmacotherapy for NASH and hepatic fibrosis. Additionally, the role of bariatric surgery in the treatment of NAFLD is still unknown. Current evidence found that NAFLD patients who undergo bariatric surgery require long-term postoperative management, due to an increased risk for fibrosis progression[[1](#_ENREF_1),[14](#_ENREF_14)].

This is the first systematic review of published NAFLD guidelines. Using AGREE II[[11](#_ENREF_11)], it systematically grades the guidelines and presents the evidence-based recommendations for the clinical management of NAFLD. Additionally, a clinical algorithm for the clinical practice was developed, based on the highly recommended guidelines.

This study has some limitations. To begin with, only the guidelines in English were included in this review. Thus, high-quality guidelines in other languages might have been missed. Second, we chose the AGREE II instrument to evaluate the guidelines, even though there are other appraisals, *e.g*. Global Rating Scale[[24](#_ENREF_24)]. Third, guidelines should include information on how to reduce inappropriate practice and improve the efficiency of management. Further, the application of guidelines is crucial in clinical practice. However, we failed to evaluate the acceptance and the application of the guidelines in this review, due to the limited inclusion in the literature included in this review.

In this study, a systematic review was conducted to search and integrate the published guidelines of NAFLD. Furthermore, based on the evaluation of the included guidelines, a clinical algorithm for the diagnosis and management of NAFLD was developed. We hope it will yield insights for physicians and policy-makers in the development and application of guidelines moving forward.

**COMMENTS**

***Background***

Non-alcoholic fatty liver disease (NAFLD) is one of the leading chronic liver diseases globally. A comprehensive study of NAFLD guidelines will be useful for various stakeholders to develop and utilize guidelines.

***Research frontiers***

New evidence supports NAFLD as a common liver disease presenting across the globe, which warrants the attention of physicians, researchers, and national policy makers. However, gaps between provider knowledge and awareness of clinical practice guidelines exist. Offering continuing education and developing high-quality national guidelines may help making inroads into the problem of suboptimal NAFLD care.

***Innovations and breakthrough***

A comprehensive study of the existing guidelines of NAFLD might be useful for helping stakeholders, including physicians, patients, policymakers and governmental bodies to develop and implement guidelines. To our knowledge, this is the first systematic critical appraisal of published guidelines to systematically grade and comprehensively present the evidence-based recommendations for the diagnosis and treatment of NAFLD.

***Applications***

The systematic review included eleven published NAFLD guidelines in the worldwide. Furthermore, we graded the guidelines, using the AGREE instrument II. Lastly, a practical algorithm for the clinical management was developed, based on the recommended guidelines.

***Terminology***

The Appraisal of Guidelines for Research and Evaluation instrument II was a tool designed to appraise the methodological rigor and transparency in which a clinical guideline is developed and it is used internationally. It consists of 23 items grouped in 6 domains, *i.e.* scope and purpose, stakeholder involvement, rigor of development, clarity and presentation, applicability and editorial independence.

***Peer-review***

The authors conducted the first systematic review of published NAFLD guidelines. It may yield insights for physicians and policy-makers in the development and application of guidelines.

**REFERENCES**

1 **Chalasani N**, Younossi Z, Lavine JE, Diehl AM, Brunt EM, Cusi K, Charlton M, Sanyal AJ. The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. *Hepatology* 2012; **55**: 2005-2023 [PMID: 22488764 DOI: 10.1002/hep.25762]

2 [**European Association for the Study of the Liver (EASL)**. Electronic address: easloffice@easloffice.eu](http://www.ncbi.nlm.nih.gov/pubmed/?term=European%20Association%20for%20the%20Study%20of%20the%20Liver%20(EASL).%20Electronic%20address%3A%20easloffice@easloffice.eu%5BCorporate%20Author%5D); [European Association for the Study of Diabetes (EASD)](http://www.ncbi.nlm.nih.gov/pubmed/?term=European%20Association%20for%20the%20Study%20of%20Diabetes%20(EASD)%5BCorporate%20Author%5D); [European Association for the Study of Obesity (EASO)](http://www.ncbi.nlm.nih.gov/pubmed/?term=European%20Association%20for%20the%20Study%20of%20Obesity%20(EASO)%5BCorporate%20Author%5D). EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. *J Hepatol* 2016; **64**: 1388-1402 [PMID: 27062661 DOI: 10.1016/j.jhep.2015.11.004]

3 **Marchesini G**, Petta S, Dalle Grave R. Diet, weight loss, and liver health in nonalcoholic fatty liver disease: Pathophysiology, evidence, and practice. *Hepatology* 2016; **63**: 2032-2043 [PMID: 26663351 DOI: 10.1002/hep.28392]

4 **Birkenfeld AL**, Shulman GI. Nonalcoholic fatty liver disease, hepatic insulin resistance, and type 2 diabetes. *Hepatology* 2014; **59**: 713-723 [PMID: 23929732 DOI: 10.1002/hep.26672]

5 **Younossi ZM**, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. *Hepatology* 2016; **64**: 73-84 [PMID: 26707365 DOI: 10.1002/hep.28431]

6 **Farrell GC**, Wong VWS, Chitturi S. NAFLD in Asia-as common and important as in the West. *Nat Rev Gastro Hepat* 2013; 10: 307-318 [PMID: 23458891 DOI: 10.1038/nrgastro.2013.34]

7 **Vernon G**, Baranova A, Younossi ZM. Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults. *Aliment Pharmacol Ther* 2011; **34**: 274-285 [PMID: 21623852 DOI: 10.1111/j.1365-2036.2011.04724.x]

8 **Masarone M**, Federico A, Abenavoli L, Loguercio C, Persico M. Non alcoholic fatty liver: epidemiology and natural history. *Rev Recent Clin Trials* 2014; **9**: 126-133 [PMID: 25514916]

9 **Zhu JZ**, Dai YN, Wang YM, Zhou QY, Yu CH, Li YM. Prevalence of Nonalcoholic Fatty Liver Disease and Economy. *Dig Dis Sci* 2015; **60**: 3194-3202 [PMID: 26017679 DOI: 10.1007/s10620-015-3728-3]

10 **Moher D**, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. *J Clin Epidemiol* 2009; **62**: 1006-1012 [PMID: 19631508 DOI: 10.1016/j.jclinepi.2009.06.005]

11 **Brouwers MC**, Kho ME, Browman GP, Burgers JS, Cluzeau F, Feder G, Fervers B, Graham ID, Grimshaw J, Hanna SE, Littlejohns P, Makarski J, Zitzelsberger L. AGREE II: advancing guideline development, reporting and evaluation in health care. *CMAJ* 2010; **182**: E839-E842 [PMID: 20603348 DOI: 10.1503/cmaj.090449]

12 **Loria P**, Adinolfi LE, Bellentani S, Bugianesi E, Grieco A, Fargion S, Gasbarrini A, Loguercio C, Lonardo A, Marchesini G, Marra F, Persico M, Prati D, Baroni GS. Practice guidelines for the diagnosis and management of nonalcoholic fatty liver disease. A decalogue from the Italian Association for the Study of the Liver (AISF) Expert Committee. *Dig Liver Dis* 2010; **42**: 272-282 [PMID: 20171943 DOI: 10.1016/j.dld.2010.01.021]

13 [**Korean Association for the Study of the Liver (KASL)**](http://www.ncbi.nlm.nih.gov/pubmed/?term=Korean%20Association%20for%20the%20Study%20of%20the%20Liver%20(KASL)%5BCorporate%20Author%5D)**.** KASL clinical practice guidelines: management of nonalcoholic fatty liver disease. *Clin Mol Hepatol* 2013; **19**: 325-348 [PMID: 24459637 DOI: 10.3350/cmh.2013.19.4.325]

14 **LaBrecque DR**, Abbas Z, Anania F, Ferenci P, Khan AG, Goh KL, Hamid SS, Isakov V, Lizarzabal M, Peñaranda MM, Ramos JF, Sarin S, Stimac D, Thomson AB, Umar M, Krabshuis J, LeMair A. World Gastroenterology Organisation global guidelines: Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. *J Clin Gastroenterol* 2014; **48**: 467-473 [PMID: 24921212 DOI: 10.1097/mcg.0000000000000116]

15 **Weiß J**, Rau M, Geier A. Non-alcoholic fatty liver disease: epidemiology, clinical course, investigation, and treatment. *Dtsch Arztebl Int* 2014; **111**: 447-452 [PMID: 25019921 DOI: 10.3238/arztebl.2014.0447]

16 **Blachier M**, Leleu H, Peck-Radosavljevic M, Valla DC, Roudot-Thoraval F. The burden of liver disease in Europe: a review of available epidemiological data. *J Hepatol* 2013; **58**: 593-608 [PMID: 23419824 DOI: 10.1016/j.jhep.2012.12.005]

17 **Spengler EK**, Loomba R. Recommendations for Diagnosis, Referral for Liver Biopsy, and Treatment of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis. *Mayo Clin Proc* 2015; **90**: 1233-1246 [PMID: 26219858 DOI: 10.1016/j.mayocp.2015.06.013]

18 **Machado MV**, Cortez-Pinto H. Non-invasive diagnosis of non-alcoholic fatty liver disease. A critical appraisal. *J Hepatol* 2013; **58**: 1007-1019 [PMID: 23183525 DOI: 10.1016/j.jhep.2012.11.021]

19 **Bedogni G**, Bellentani S, Miglioli L, Masutti F, Passalacqua M, Castiglione A, Tiribelli C. The Fatty Liver Index: a simple and accurate predictor of hepatic steatosis in the general population. *BMC Gastroenterol* 2006; **6**: 33 [PMID: 17081293 DOI: 10.1186/1471-230X-6-33]

20 **Lee JH**, Kim D, Kim HJ, Lee CH, Yang JI, Kim W, Kim YJ, Yoon JH, Cho SH, Sung MW, Lee HS. Hepatic steatosis index: a simple screening tool reflecting nonalcoholic fatty liver disease. *Dig Liver Dis* 2010; **42**: 503-508 [PMID: 19766548 DOI: 10.1016/j.dld.2009.08.002]

21 **Marchesini G**, Mazzotti A. NAFLD incidence and remission: only a matter of weight gain and weight loss? *J Hepatol* 2015; **62**: 15-17 [PMID: 25450705 DOI: 10.1016/j.jhep.2014.10.023]

22 **Sanyal AJ**, Friedman SL, McCullough AJ, Dimick-Santos L. Challenges and opportunities in drug and biomarker development for nonalcoholic steatohepatitis: findings and recommendations from an American Association for the Study of Liver Diseases-U.S. Food and Drug Administration Joint Workshop. *Hepatology* 2015; **61**: 1392-1405 [PMID: 25557690 DOI: 10.1002/hep.27678]

23 **Wilkins T**, Tadkod A, Hepburn I, Schade RR. Nonalcoholic fatty liver disease: diagnosis and management. *Am Fam Physician* 2013; **88**: 35-42 [PMID: 23939604]

24 **Sint Nicolaas J**, de Jonge V, de Man RA, ter Borg F, Cahen DL, Moolenaar W, Stolk MF, van Tilburg AJ, Valori RM, van Leerdam ME, Kuipers EJ. The Global Rating Scale in clinical practice: a comprehensive quality assurance programme for endoscopy departments. *Dig Liver Dis* 2012; **44**: 919-924 [PMID: 22840567 DOI: 10.1016/j.dld.2012.06.021]

25 **Chitturi S**, Farrell GC, Hashimoto E, Saibara T, Lau GK, Sollano JD. Non-alcoholic fatty liver disease in the Asia-Pacific region: definitions and overview of proposed guidelines. *J Gastroenterol Hepatol* 2007; **22**: 778-787 [PMID: 17565630 DOI: 10.1111/j.1440-1746.2007.05001.x]

26 **Zeng MD**, Fan JG, Lu LG, Li YM, Chen CW, Wang BY, Mao YM. Guidelines for the diagnosis and treatment of nonalcoholic fatty liver diseases. *J Dig Dis* 2008; **9**: 108-112 [PMID: 18419645 DOI: 10.1111/j.1751-2980.2008.00331.x]

27 **Fan JG**, Jia JD, Li YM, Wang BY, Lu LG, Shi JP, Chan LY. Guidelines for the diagnosis and management of nonalcoholic fatty liver disease: update 2010: (published in Chinese on Chinese Journal of Hepatology 2010; 18: 163-166). *J Dig Dis* 2011; **12**: 38-44 [PMID: 21276207 DOI: 10.1111/j.1751-2980.2010.00476.x]

28 **Gao X**, Fan JG. Diagnosis and management of non-alcoholic fatty liver disease and related metabolic disorders: consensus statement from the Study Group of Liver and Metabolism, Chinese Society of Endocrinology. *J Diabetes* 2013; **5**: 406-415 [PMID: 23560695 DOI: 10.1111/1753-0407.12056]

29 **Arab JP**, Candia R, Zapata R, Muñoz C, Arancibia JP, Poniachik J, Soza A, Fuster F, Brahm J, Sanhueza E, Contreras J, Cuellar MC, Arrese M, Riquelme A. Management of nonalcoholic fatty liver disease: an evidence-based clinical practice review. *World J Gastroenterol* 2014; **20**: 12182-12201 [PMID: 25232252 DOI: 10.3748/wjg.v20.i34.12182]

30 **Watanabe S**, Hashimoto E, Ikejima K, Uto H, Ono M, Sumida Y, Seike M, Takei Y, Takehara T, Tokushige K, Nakajima A, Yoneda M, Saibara T, Shiota G, Sakaida I, Nakamuta M, Mizuta T, Tsubouchi H, Sugano K, Shimosegawa T. Evidence-based clinical practice guidelines for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. *J Gastroenterol* 2015; **50**: 364-377 [PMID: 25708290 DOI: 10.1007/s00535-015-1050-7]

**P-Reviewer:** Abenavoli L, Lee HC, Torabizadeh Z **S-Editor:** Gong ZM

**L-Editor:** **E-Editor:**

**Specialty type:** Gastroenterology and hepatology

**Country of origin:** China

**Peer-review report classification**

Grade A (Excellent): A

Grade B (Very good): B

Grade C (Good): C

Grade D (Fair): 0

Grade E (Poor): 0

**Table 1 Characteristics of non-alcoholic fatty liver disease guidelines included in this study**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Author(s)/ Organization(s)** | **Published Year** | **Region/ country** | **Title** | **Recommendation** |
| Chitturi *et al*[[25](#_ENREF_25)]. Asia–Pacific Working Party on NAFLD (APWP 07) | 2007 | Asia–Pacific region | Non-alcoholic fatty liver disease in the Asia-Pacific region: definitions and overview of proposed guidelines | not recommended |
| Zeng *et al*[[26](#_ENREF_26)]. The Chinese National Consensus Workshop on NAFLD (China 08)  | 2008 | China | Guidelines for the diagnosis and treatment of nonalcoholic fatty liver diseases | not recommended |
| Loria *et al*[[12](#_ENREF_12)]. Italian Association for the Study of the Liver (Italy 10)  | 2010 | Italy | Practice guidelines for the diagnosis and management of nonalcoholic fatty liver disease: A decalogue from the Italian Association for the Study of the Liver (AISF) Expert Committee | recommended but modified |
| Fan *et al*[[27](#_ENREF_27)]. Chinese Association for the Study of Liver Disease (China 11)  | 2011 | China | Guidelines for the diagnosis and management of nonalcoholic fatty liver disease: Update 2010 | not recommended |
| Chalasani *et al*[[1](#_ENREF_1)]. American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association (US 12)  | 2012 | United States | The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association | recommended |
| The Korean Association for the Study of the Liver (South Korea 13)[[13](#_ENREF_13)] | 2013 | South Korea | KASL clinical practice guidelines: Management of nonalcoholic fatty liver disease | recommended but modified |
| Gao *et al*[[28](#_ENREF_28)]. Study Group of Liver and Metabolism, Chinese Society of Endocrinology (China 13)  | 2013 | China | Diagnosis and management of non-alcoholic fatty liver disease and related metabolic disorders: Consensus statement from the Study Group of Liver and Metabolism, Chinese Society of Endocrinology | not recommended |
| Arab *et al*[[29](#_ENREF_29)]. Chilean Society of Gastroenterology (Chile 14)  | 2014 | Chile | Management of nonalcoholic fatty liver disease: An evidence-based clinical practice review | not recommended |
| LaBrecque *et al*[[14](#_ENREF_14)]. World Gastroenterology Organization (WGO 14) | 2014 | World | World Gastroenterology Organization global guidelines: Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis | not recommended |
| Watanabe, S., et al. Japanese Society of Gastroenterology (Japan 15) [[30](#_ENREF_30)] | 2015 | Japan | Evidence-based clinical practice guidelines for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis | not recommended |
| European Association for the Study of the Liver, European Association for the Study of Diabetes and European Association for the Study of Obesity (Europe 16)[[2](#_ENREF_2)] | 2016 | Europe | EASL–EASD–EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease | recommended |

Ordered by publication year. Recommendation was developed based on AGREE II instrument.



**Figure 1 Flow chart of guidelines searching.**



**Figure 2 Domain scores for each guideline based on the Appraisal of Guidelines for Research and Evaluation II Instrument.** A-C: each Appraisal of Guidelines for Research and Evaluation II domain score for guidelines is presented on the x-axis as a percentage of 100 (0% = the domain was not at all satisfied; and100% = fully satisfied. D: overall scores for guidelines. WGO: World Gastroenterology Organization.



**Figure 3 Clinical algorithm for the diagnosis and management of** **non-alcoholic fatty liver disease in adults.** The algorithm was developed according to United States 12[1], WGO 14[13] and Europe 16[2]. 1H-MRS: proton magnetic resonance spectroscopy; ALT: alanine transaminase; AST: aspartate transaminase; BMI: body mass index; CT: computed tomography; FPG: fasting plasma glucose; FXR: farnesoid X receptor; GGT: gamma-glutamyltransferase; HbA1c: hemoglobin a1c; HOMA-IR: homeostasis model assessment of insulin resistance; MRI: magnetic resonance imaging; WHR: waist-to-hip ratio; WGO: World Gastroenterology Organization.